Inokain eye drops 0.4% 5 ml
Condition: New product
995 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Oxybuprocaine
Release form
Drops
Composition
Oxybuprocain hydrochloride 4 mg. Auxiliary substances: benzalkonium chloride, boric acid, disodium edetate, sodium chloride, water d / and.
Pharmacological effect
Local anesthetic that blocks nerve endings. When applied topically, it penetrates well into tissues. Compared with tetracaine and other local anesthetics, it has a less pronounced irritant effect on the conjunctiva and cornea. Surface anesthesia of the conjunctiva and the cornea after applying eye drops occurs after 30 seconds and lasts for 15 minutes.
Pharmacokinetics
Inokain easily penetrates the corneal stroma after a single instillation into the conjunctival cavity. Over the next 15 minutes, a quantitative decrease in the stromal concentration of the drug is observed, which ensures a 12-15 minute period of anesthesia with a single instillation.
Indications
Local anesthesia in ophthalmology: - measurement of intraocular pressure (tonometry) - gonioscopy — diagnostic conjunctival scraping — removal of foreign bodies and stitches from the cornea and conjunctiva — short-term surgical interventions on the cornea and conjunctiva.
Contraindications
- hypersensitivity to the drug.
Use during pregnancy and lactation
Clinical experience in the use of the drug during pregnancy and lactation is not enough. The use of Inokain during pregnancy and during breastfeeding is possible only in cases where the expected benefit of therapy for the mother outweighs the potential risk to the fetus or infant.
Dosage and administration
The drug is instilled into the conjunctival sac 1 drop. Long-term anesthesia (up to 1 h) provides 3-time instillation with an interval of 4-5 minutes.
Side effects
Possible: short-term tingling sensation, burning and hyperemia of the conjunctiva, allergic reactions. Rarely: keratitis.
Overdose
Data overdose of the drug is not available.
Interaction with other drugs
Negative or positive effects are not described in the literature with simultaneous administration of oxybuprocaine and other eye drops traditionally used in the conjunctival sac.It is noted that oxybuprocaine can theoretically reduce the antibacterial activity of sulfonamides.
special instructions
The drug is intended only for instillation in the conjunctival sac. Do not use for injections. Not intended for long-term therapy in the complex treatment of eye diseases. Prolonged, repeated and prolonged use (as well as other local anesthetics) can lead to persistent corneal opacification. During anesthesia, it is necessary to protect the eye from irritating chemical effects, foreign bodies and friction. Use in pediatrics Sufficient experience in the use of the drug in children do not. The use of Inokain in children is possible only in cases where the expected benefit of therapy exceeds the risk of possible side effects.